A drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day.Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S.
National Institute of Allergy and Infectious Diseases. The result have not yet been published or reviewed by independent scientists.The study tested baricitinib, a pill that Indianapolis-based Lilly already sells as Olumiant to treat rheumatoid arthritis, the less common form of arthritis that occurs when a mistaken or overreacting immune system attacks joints, causing inflammation.